Biosimilar Education And Innovation Bills Head To Biden’s Desk
Senators, Industry And Regulators Urge President To Pass Bipartisan Bills
Executive Summary
The Advancing Education on Biosimilars Act and the Ensuring Innovation Act will be looked at by the US President Joe Biden, after receiving the approval of both the Senate and the House of Representatives. The bills are aimed at lowering prescription drug costs and saving overall healthcare costs.
You may also be interested in...
Cutting Through The Confusion On US Biosimilar Interchangeability
Amid ongoing confusion around the US interchangeability designation for biosimilars, Joseph Park and Gillian Woollett of Samsung Bioepis talk about the risks of misinformation, the importance of educational efforts, and how language is shaping certain misunderstandings.
Cutting Through The Confusion On US Biosimilar Interchangeability
Amid ongoing confusion around the US interchangeability designation for biosimilars, Joseph Park and Gillian Woollett of Samsung Bioepis talk to Generics Bulletin about the risks of misinformation, the importance of educational efforts, and how language is shaping certain misunderstandings around biosimilars.
Amgen Urges Balance In US Biosimilars Policy
Amgen’s recent study on biosimilars trends has outlined the importance of US policy in the success of the biosimilars marketplace, insisting on the importance of increased competition and effective reimbursement and education policies. But with interests in innovative biologics as well as biosimilars, the company has also emphasized that pro-biosimilars policies must not stifle innovation and compromise free competition.